LONDON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (“DMT”) therapies, has today ...
Company advances ongoing clinical trials with Phase I completed and dosing initiated in Phase IIa trial for lead product candidate, SPL026, a DMT-assisted therapy for the treatment of Major Depressive ...
LONDON, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced that the previously issued: ...
Successful completion of listing on TSX Venture Exchange $58 million financing enables potential rapid advancement of Small Pharma’s patent portfolio LONDON, United Kingdom, July 30, 2021 (GLOBE NEWSWIRE) -- Small ...
Copyright © 2015 - 2021 Lifecarenews.in
